Lexeo Therapeutics Ownership | Who Owns Lexeo Therapeutics?

Lexeo Therapeutics Ownership Summary

Lexeo Therapeutics is owned by 75.57% institutional investors, 0.80% insiders, and 23.64% retail investors. Balyasny asset management is the largest institutional shareholder, holding 12.11% of LXEO shares.

LXEO Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Lexeo Therapeutics	75.57%	0.80%	23.64%
Sector	Healthcare Stocks	232.20%	10.74%	-142.94%
Industry	Biotech Stocks	382.11%	10.55%	-292.66%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Balyasny asset management	4.01M	12.11%	$16.12M
Frazier life sciences management	4.42M	10.15%	$29.38M
Affinity asset advisors	3.87M	8.88%	$25.70M
Blackrock funding, inc. /de	4.91M	8.05%	$48.73M
Vestal point capital, lp	3.25M	7.46%	$21.58M
Vanguard group	3.89M	6.39%	$38.67M
Woodline partners lp	2.57M	5.90%	$17.08M
Point72 asset management	1.94M	4.46%	$12.89M
Adar1 capital management	1.53M	3.52%	$10.17M
Blackstone	1.12M	2.58%	$7.47M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Caxton	13.94K	3.24%	$138.45K
Affinity asset advisors	3.87M	2.24%	$25.70M
Vestal point capital, lp	3.25M	0.97%	$21.58M
Adar1 capital management	1.53M	0.96%	$10.17M
Frazier life sciences management	4.42M	0.88%	$29.38M
Silverarc capital management	617.61K	0.85%	$6.13M
Dafna capital management	358.08K	0.59%	$2.38M
Ikarian capital	567.60K	0.38%	$3.77M
Privium fund management b.v.	192.55K	0.35%	$1.91M
Nantahala capital management	1.00M	0.33%	$9.93M

Top Buyers

Holder	Shares	% Assets	Change
Balyasny asset management	4.01M	0.02%	4.01M
Blackrock funding, inc. /de	4.91M	0.00%	2.74M
Vanguard group	3.89M	0.00%	1.67M
Adar1 capital management	1.53M	0.96%	1.39M
Point72 asset management	1.94M	0.02%	1.29M

Top Sellers

Holder	Shares	% Assets	Change
Eventide asset management	-	-	-1.23M
Omega fund management	-	-	-1.18M
Novo	-	-	-1.12M
Ally bridge group (ny)	-	-	-867.30K
Ra capital management	-	-	-546.55K

New Positions

Holder	Shares	% Assets	Change	Value
Balyasny asset management	4.01M	0.02%	4.01M	$16.12M
Nantahala capital management	1.00M	0.33%	1.00M	$9.93M
683 capital management	922.66K	0.32%	922.66K	$6.13M
Y-intercept (hong kong)	231.16K	0.05%	231.16K	$2.30M
Ameriprise financial	166.54K	0.00%	166.54K	$1.11B

Sold Out

Holder	Change
Coldstream capital management	-93.00
Nelson, van denburg & campbell wealth management group	-185.00
Bryn mawr trust	-406.00
Comerica bank	-1.76K
Skopos labs	-3.85K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	111	-	46,081,879	-6.64%	75	1.15%	83	7.79%	17	13.33%
Sep 30, 2025	108	20.00%	49,357,573	16.76%	113	0.70%	74	34.55%	15	-
Jun 30, 2025	89	2.30%	42,266,176	54.77%	127	1.88%	54	35.00%	15	-34.78%
Mar 31, 2025	91	4.60%	28,007,979	-3.59%	84	1.10%	42	-26.32%	23	109.09%
Dec 31, 2024	89	32.84%	29,519,159	-0.73%	89	1.10%	59	13.46%	11	37.50%

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 18, 2026	Otero Jose Manuel	Chief Operating Officer	Sell	$19.29K
Feb 18, 2026	Townsend Richard Nolan	Chief Executive Officer	Sell	$64.92K
Nov 18, 2025	Otero Jose Manuel	Chief Operating Officer	Sell	$6.68K
Nov 18, 2025	Townsend Richard Nolan	Chief Executive Officer	Sell	$10.45K
Nov 18, 2025	Adler Eric	Chief Medical Officer	Sell	$5.70K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	2
2025 Q4	-	14
2025 Q3	-	5
2025 Q2	-	4
2025 Q1	-	4

LXEO Ownership FAQ

Who Owns Lexeo Therapeutics?

Lexeo Therapeutics shareholders are primarily institutional investors at 75.57%, followed by 0.80% insiders and 23.63% retail investors. The average institutional ownership in Lexeo Therapeutics's industry, Biotech Stocks , is 382.11%, which Lexeo Therapeutics falls below.

Who owns the most shares of Lexeo Therapeutics?

Lexeo Therapeutics’s largest shareholders are Balyasny asset management (4.01M shares, 12.11%), Frazier life sciences management (4.42M shares, 10.15%), and Affinity asset advisors (3.87M shares, 8.88%). Together, they hold 31.14% of Lexeo Therapeutics’s total shares outstanding.

Does Blackrock own Lexeo Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Lexeo Therapeutics.

Who is Lexeo Therapeutics’s biggest shareholder by percentage of total assets invested?

Caxton is Lexeo Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.24% of its assets in 13.94K Lexeo Therapeutics shares, valued at 138.45K$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools